139 related articles for article (PubMed ID: 6377216)
21. A pharmacological study on pegylated asparaginase used in front-line treatment of children with acute lymphoblastic leukemia.
Rizzari C; Citterio M; Zucchetti M; Conter V; Chiesa R; Colombini A; Malguzzi S; Silvestri D; D'Incalci M
Haematologica; 2006 Jan; 91(1):24-31. PubMed ID: 16434367
[TBL] [Abstract][Full Text] [Related]
22. L-asparaginase--antileukemia agent.
Bukhari SZ; Yaqub M
J Pak Med Assoc; 1977 Jan; 27(1):262-4. PubMed ID: 19639
[TBL] [Abstract][Full Text] [Related]
23. Sequential combination of methotrexate and L-asparaginase in the treatment of refractory acute leukemia.
Amadori S; Tribalto M; Pacilli L; De Laurentis C; Papa G; Mandelli F
Cancer Treat Rep; 1980; 64(8-9):939-42. PubMed ID: 6934851
[TBL] [Abstract][Full Text] [Related]
24. Long-term results of a randomized trial on extended use of high dose L-asparaginase for standard risk childhood acute lymphoblastic leukemia.
Pession A; Valsecchi MG; Masera G; Kamps WA; Magyarosy E; Rizzari C; van Wering ER; Lo Nigro L; van der Does A; Locatelli F; Basso G; Aricò M
J Clin Oncol; 2005 Oct; 23(28):7161-7. PubMed ID: 16192600
[TBL] [Abstract][Full Text] [Related]
25. Gel entrapped L-asparaginase: kinetic behavior and antitumor activity.
O'Driscoll KF; Korus RA; Ohnuma T; Walczack IM
J Pharmacol Exp Ther; 1975 Nov; 195(2):382-8. PubMed ID: 241845
[TBL] [Abstract][Full Text] [Related]
26. A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L-asparaginase: results of the Prophylactic Antithrombin Replacement in Kids with Acute Lymphoblastic Leukemia Treated with Asparaginase (PARKAA) Study.
Mitchell LG; Andrew M; Hanna K; Abshire T; Halton J; Anderson R; Cherrick I; Desai S; Mahoney D; McCuster P; Wu J; Dahl G; Chait P; de Veber G; Lee KJ; Mikulis D; Ginsberg J; Way C;
Cancer; 2003 Jan; 97(2):508-16. PubMed ID: 12518376
[TBL] [Abstract][Full Text] [Related]
27. Synthesis, characterization and immunogenicity of silk fibroin-L-asparaginase bioconjugates.
Zhang YQ; Zhou WL; Shen WD; Chen YH; Zha XM; Shirai K; Kiguchi K
J Biotechnol; 2005 Nov; 120(3):315-26. PubMed ID: 16102867
[TBL] [Abstract][Full Text] [Related]
28. Comparison of anaphylactic reactions to asparaginase derived from Escherichia coli and from Erwinia cultures.
Dellinger CT; Miale TD
Cancer; 1976 Oct; 38(4):1843-6. PubMed ID: 791476
[TBL] [Abstract][Full Text] [Related]
29. Immunoglobulin and granulocyte cytochemical reactions in L-asparaginase treated children with acute lymphoblastic leukemia.
Zajaczkowski L; Pituch A; Legutko L
Med Interne; 1976; 14(3):191-5. PubMed ID: 1071477
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetics and drug monitoring of L-asparaginase treatment.
Boos J
Int J Clin Pharmacol Ther; 1997 Mar; 35(3):96-8. PubMed ID: 9088996
[TBL] [Abstract][Full Text] [Related]
31. [Immunization against L-asparaginase. Demonstration and characteristics of antibodies. Clinical value].
Marsalet YD; Lambert G; Hornez JP; Bauters F; Goudemand M
Nouv Presse Med; 1973 Jun; 2(23):1575-8. PubMed ID: 4197351
[No Abstract] [Full Text] [Related]
32. [Improved measurements of anti-L-asparaginase IgG antibody and its clinical applications].
Tsukimoto I; Matsui J; Iwashita H; Shigeta K; Suzuki H; Hashimoto T
Rinsho Ketsueki; 1992 Jan; 33(1):24-9. PubMed ID: 1545512
[TBL] [Abstract][Full Text] [Related]
33. Anti-Erwinia asparaginase antibodies during treatment of childhood acute lymphoblastic leukemia and their relationship to outcome: a case-control study.
Klug Albertsen B; Schmiegelow K; Schrøder H; Carlsen NT; Rosthøj S; Avramis VI; Jakobsen P
Cancer Chemother Pharmacol; 2002 Aug; 50(2):117-20. PubMed ID: 12172975
[TBL] [Abstract][Full Text] [Related]
34. Immunological and pharmacological characterization of poly-DL-alanyl-modified Erwinia carotovora L-asparaginase.
Uren JR; Hargis BJ; Beardsley P
Cancer Res; 1982 Oct; 42(10):4068-71. PubMed ID: 7105004
[TBL] [Abstract][Full Text] [Related]
35. Mapping of B-cell epitopes in E. coli asparaginase II, an enzyme used in leukemia treatment.
Werner A; Röhm KH; Müller HJ
Biol Chem; 2005 Jun; 386(6):535-40. PubMed ID: 16006240
[TBL] [Abstract][Full Text] [Related]
36. Antithrombin supplementation III in childhood acute lymphoblastic leukemia treated with L-asparaginase.
Matsuzaki A; Suminoe A; Hara T
Pediatr Hematol Oncol; 2002 Dec; 19(8):601-3. PubMed ID: 12487838
[TBL] [Abstract][Full Text] [Related]
37. Distinct fluctuations of ammonia levels during asparaginase therapy for childhood acute leukemia.
Steiner M; Attarbaschi A; Kastner U; Dworzak M; Haas OA; Gadner H; Mann G
Pediatr Blood Cancer; 2007 Oct; 49(5):640-2. PubMed ID: 16941647
[TBL] [Abstract][Full Text] [Related]
38. [Preliminary study on the safety and pharmacodynamic action of low dose L-asparaginase].
Wu ZL; Chen FX; Ye TZ; Lai YH; Cui YQ; Zou YW; Lu CY; Lan SL; Zhong GY; Guan JM; Wei FG; Zhang H
Zhonghua Xue Ye Xue Za Zhi; 2006 Jan; 27(1):14-6. PubMed ID: 16732932
[TBL] [Abstract][Full Text] [Related]
39. An isocratic fluorescence HPLC assay for the monitoring of l-asparaginase activity and l-asparagine depletion in children receiving E. colil-asparaginase for the treatment of acute lymphoblastic leukaemia.
Nath CE; Dallapozza L; Eslick AE; Misra A; Carr D; Earl JW
Biomed Chromatogr; 2009 Feb; 23(2):152-9. PubMed ID: 18823071
[TBL] [Abstract][Full Text] [Related]
40. L-Asparaginase as a single agent in acute lymphocytic leukemia: survey of studies form Childrens Cancer Study Group.
Nesbit ME; Ertel I; Hammond GD
Cancer Treat Rep; 1981; 65 Suppl 4():101-7. PubMed ID: 7049373
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
